Krystal Biotech, Inc. (KRYS) financial statements (2022 and earlier)

Company profile

Business Address 2100 WHARTON STREET
PITTSBURGH, PA 15203
State of Incorp.
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:438,100271,300193,70049,591
Cash and cash equivalents341,246268,269187,51449,591
Short-term investments96,8502,9936,171 
Other undisclosed cash, cash equivalents, and short-term investments43815 
Prepaid expense   304
Other current assets   19
Other undisclosed current assets4,1673,7582,180 
Total current assets:442,267275,058195,88049,914
Noncurrent Assets
Operating lease, right-of-use asset7,2283,2982,709
Property, plant and equipment112,35530,8768,475200
Long-term investments and receivables64,371 497 
Long-term investments64,371 497 
Other noncurrent assets741,6121,462 
Total noncurrent assets:184,02835,78613,143200
TOTAL ASSETS:626,295310,844209,02350,114
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10,4092,747796270
Accounts payable8,3982,105724193
Accrued liabilities2,0116427277
Debt  480 
Other liabilities872619 
Other undisclosed current liabilities15,24012,6792,032370
Total current liabilities:25,73615,4523,327640
Noncurrent Liabilities
Long-term debt and lease obligation6,9833,3082,782 
Operating lease, liability6,9833,3082,782
Other undisclosed noncurrent liabilities(6,983)(3,308)  
Total noncurrent liabilities:6,9833,3082,782 
Total liabilities:32,71918,7606,109640
Stockholders' equity
Stockholders' equity attributable to parent593,576292,084202,91449,474
Additional paid in capital734,523363,292241,95158,544
Accumulated other comprehensive income (loss)(163)610 
Accumulated deficit(140,784)(71,214)(39,047)(9,070)
Total stockholders' equity:593,576292,084202,91449,474
TOTAL LIABILITIES AND EQUITY:626,295310,844209,02350,114

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2017
Operating expenses(68,275)(32,999)(22,081)(4,772)
Other undisclosed operating income 3367 
Operating loss:(68,275)(32,999)(22,081)(4,772)
Nonoperating expense   (3,148)
Interest and debt expense(1,492)   
Net loss:(69,767)(32,999)(22,081)(7,920)
Other undisclosed net income attributable to parent1978322,993 
Net loss available to common stockholders, diluted:(69,570)(32,167)(19,088)(7,920)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2017
Net loss:(69,767)(32,999)(22,081)(7,920)
Comprehensive loss:(69,767)(32,999)(22,081)(7,920)
Other undisclosed comprehensive income, net of tax, attributable to parent288283,001 
Comprehensive loss, net of tax, attributable to parent:(69,739)(32,171)(19,080)(7,920)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: